FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

•••	.g.c, .	o.o		

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Hatzis-Schoch Brent						2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [ BDTX ]								Check	tionship of Reporting all applicable) Director Officer (give title		g Pers	Person(s) to Issuer 10% Owner Other (specify	
(Last) C/O BLA 139 MA		3. Date of Earliest Transaction (Month/Day/Year) 12/14/2020								X	below) below)  See Remarks								
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)				_   4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv ine) X						
		Tab	le I - I	Non-Deri	vative	e Sec	uriti	ies A	cquired	, D	isposed o	of, or B	enefici	ally	Owned	t			
1. Title of Security (Instr. 3) 2. To Date			2. Transact Date (Month/Day	ion 2A. De Execu		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or			5. Ai Secu Bend Own		ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code V	,	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common	Stock			12/14/2	:020	20		М		4,078	Α	\$3	3.2		7,078		D		
Common Stock 12/14/202				:020	20		S <sup>(1)</sup>		4,078	D	\$34.94	9491 <sup>(2)</sup>		3,000		D			
		Т	able								sposed of , converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	eemed tion Date, n/Day/Year)	4. Transa Code ( 8)	5. Number action of		6. Date Exerci Expiration Dat (Month/Day/Ye		ate	7. Title and Amount of Securities Underlying Derivative Securii (Instr. 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	cisable	Expiration Date	Title	Amour or Number of Shares	er					
Stock Option (Right to	\$3.2	12/14/2020			M			4,078	(3)		06/11/2029	Common Stock	4,078	8	\$0.00	186,264	4	D	

## **Explanation of Responses:**

- $1. \ Shares \ sold\ pursuant\ to\ a\ pre-established\ 10b5-1\ trading\ plan\ effective\ as\ of\ June\ 12,\ 2020$
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.77 to \$35.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

## Remarks:

Chief Operating Officer and General Counsel

<u>/s/ Brent Hatzis-Schoch</u>
\*\* Signature of Reporting Person

12/16/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.